Announced Date: 2025-12-04 (December 4, 2025)
Licensor (Seller): Kelun-Biotech (China)
Licensee (Buyer): Crescent Biopharma (US) (Nasdaq: CBIO),
.
Kelun’s Asset Name: SKB105 (CR-003)
Asset Modality: Antibody-drug conjugate (ADC)
Antibody Target: integrin beta-6 (ITGB6)-directed, fully human IgG1 monoclonal antibody
ADC Payload: topoisomerase 1 inhibitor payload
ADC Linker: clinically validated cleavable linker
Potential Indication: treatment of solid tumors
Current Stage: Clinic-ready
.
Scope of Authority:
Crescent has granted Kelun-Biotech exclusive rights to research, develop, manufacture and commercialize CR-001 in Greater China (including mainland China, Hong Kong, Macau and Taiwan).
Crescent ’s lead program CR-001, a PD-1 x VEGF bispecific antibody
.
In addition, Kelun-Biotech has granted Crescent exclusive rights to research, develop, manufacture and commercialize SKB105 in the United States, Europe and all other markets outside of Greater China.
.
The partnership includes the development of these candidates as monotherapies, and also the evaluation of CR-001 in combination with SKB105.
.
Both Crescent and Kelun-Biotech have the right to independently develop CR-001 in additional combinations, including combinations of CR-001 with proprietary ADC pipeline assets.
.
.
Payment Detail:
Kelun-Biotech will receive an upfront payment of US$80 million from Crescent and is also eligible to receive additional milestones of up to US$1.25 billion, plus tiered middle single-digit to low double-digit royalties on net sales of SKB105.
Kelun-Biotech is also eligible to receive additional payment from Crescent if Crescent undergoes a near-term change of control or enters into a sublicense agreement with a third party.
.
Crescent will receive an upfront payment of US$20 million from Kelun-Biotech and is also eligible to receive additional milestones of up to US$30 million, plus tiered low to middle single digit royalties on net sales of CR-001.
.
Link:
.
.
Note:
Chinese Name of Kelun-Biotech, 科伦博泰
